{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:28Z","timestamp":1791932368642,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.ppat.1010658","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000}}],"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"CEPI","doi-asserted-by":"crossref","award":["276880"],"award-info":[{"award-number":["276880"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors.<\/jats:p>","DOI":"10.1371\/journal.ppat.1010658","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T13:37:01Z","timestamp":1656337021000},"page":"e1010658","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-4599","authenticated-orcid":true,"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Tussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Scappaticci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaddeus G.","family":"Pullano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary D.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Vasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan L.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Kroon","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha R.","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Tad","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina V.","family":"Costecalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan H.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Hawks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"issue":"1","key":"ppat.1010658.ref001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/01652176.2019.1580827","article-title":"Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review.","volume":"39","author":"RK Singh","year":"2019","journal-title":"Vet Q."},{"issue":"9","key":"ppat.1010658.ref002","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3201\/eid2309.161922","article-title":"Convergence of Humans, Bats, Trees, and Culture in Nipah Virus Transmission, Bangladesh","volume":"23","author":"ES Gurley","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"22","key":"ppat.1010658.ref003","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"BL DeBuysscher","year":"2014","journal-title":"Vaccine"},{"issue":"24","key":"ppat.1010658.ref004","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.vaccine.2015.03.089","article-title":"Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease","volume":"33","author":"J Prescott","year":"2015","journal-title":"Vaccine"},{"key":"ppat.1010658.ref005","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment.","volume":"1","author":"TP Monath","year":"2019","journal-title":"Vaccine X"},{"key":"ppat.1010658.ref006","unstructured":"Food & Drug Administration Prescribing Information, ERVEBO (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection Initial U.S. Approv al: 2019. https:\/\/www.fda.gov\/media\/133748\/download"},{"key":"ppat.1010658.ref007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2020.09.005","article-title":"Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003\/TV005.","volume":"43","author":"AP Durbin","year":"2020","journal-title":"Curr Opin Virol."},{"issue":"1","key":"ppat.1010658.ref008","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"TP Monath","year":"2015","journal-title":"Vaccine"},{"key":"ppat.1010658.ref009","volume-title":"Replicating Vaccines-a New Generation","author":"R Rappuoli","year":"2010"},{"issue":"9-10","key":"ppat.1010658.ref010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.micinf.2018.01.005","article-title":"Measles-derived vaccines to prevent emerging viral diseases","volume":"20","author":"PN Frantz","year":"2018","journal-title":"Microbes Infect"},{"key":"ppat.1010658.ref011","doi-asserted-by":"crossref","first-page":"197662","DOI":"10.1016\/j.virusres.2019.197662","article-title":"Characterization of a replication-competent vector encoding DsRed based on a human adenovirus type 4 a-like strain","volume":"270","author":"X Tian","year":"2019","journal-title":"Virus Res"},{"issue":"6","key":"ppat.1010658.ref012","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/v6062392","article-title":"Alphavirus-based vaccines.","volume":"6","author":"K. Lundstrom","year":"2014","journal-title":"Viruses"},{"issue":"1","key":"ppat.1010658.ref013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-021-00282-y","article-title":"A single-dose live attenuated chimeric vaccine candidate against Zika virus","volume":"6","author":"WX Chin","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"10","key":"ppat.1010658.ref014","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jmv.21587","article-title":"Safety evaluation of chimeric Langat\/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis","volume":"81","author":"NS Pripuzova","year":"2009","journal-title":"J Med Virol"},{"issue":"5","key":"ppat.1010658.ref015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.vaccine.2009.11.037","article-title":"Stable expression of a foreign protein by a replication-competent rubella viral vector","volume":"28","author":"A Spadaccini","year":"2010","journal-title":"Vaccine"},{"issue":"19","key":"ppat.1010658.ref016","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1128\/JVI.00550-09","article-title":"Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques","volume":"83","author":"R Xu","year":"2009","journal-title":"J Virol"},{"issue":"44","key":"ppat.1010658.ref017","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1016\/j.vaccine.2019.09.027","article-title":"Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine","volume":"37","author":"OS Kumru","year":"2019","journal-title":"Vaccine"},{"issue":"34","key":"ppat.1010658.ref018","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1016\/j.vaccine.2012.06.001","article-title":"Recombinant canine distemper virus serves as bivalent live vaccine against rabies and canine distemper","volume":"30","author":"X Wang","year":"2012","journal-title":"Vaccine"},{"key":"ppat.1010658.ref019","doi-asserted-by":"crossref","first-page":"15327","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.","volume":"8","author":"SM Kallert","year":"2017","journal-title":"Nat Commun."},{"issue":"4","key":"ppat.1010658.ref020","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/JVI.76.4.1649-1662.2002","article-title":"Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G\/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system","volume":"76","author":"SG Lee","year":"2002","journal-title":"J Virol"},{"key":"ppat.1010658.ref021","article-title":"IABs scientific workshop on neurovirulence tests for live virus vaccines, January 31-February 1, 2005, Geneva"},{"issue":"7","key":"ppat.1010658.ref022","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/vaccines9070710","article-title":"Live Viral Vaccine Neurovirulence Screening: Current and Future Models.","volume":"9","author":"C May Fulton","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"21","key":"ppat.1010658.ref023","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1073\/pnas.89.21.10532","article-title":"Construction and characterization of chimeric tick-borne encephalitis\/dengue type 4 viruses","volume":"89","author":"AG Pletnev","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1010658.ref024","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcdb.2011.12.005","article-title":"Ephrin-B2 and ephrin-B3 as functional henipavirus receptors","volume":"23","author":"K Xu","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"ppat.1010658.ref025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bpa.12278","article-title":"Henipavirus Encephalitis: Recent Developments and Advances","volume":"25","author":"KC Ong","year":"2015","journal-title":"Brain Pathol"},{"issue":"51","key":"ppat.1010658.ref026","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment.","volume":"34","author":"DK Clarke","year":"2016","journal-title":"Vaccine"},{"key":"ppat.1010658.ref027","unstructured":"World Health Organization. WHO Guidelines On Nonclinical Evaluation Of Vaccines. WHO Technical Report Series, No. 927, 2005, https:\/\/www.who.int\/publications\/m\/item\/annex1-nonclinical.p31-63"},{"issue":"4","key":"ppat.1010658.ref028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-1157(87)80003-3","article-title":"The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination.","volume":"15","author":"IS Levenbook","year":"1987","journal-title":"J Biol Stand."},{"issue":"13","key":"ppat.1010658.ref029","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/JVI.00709-15","article-title":"Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors","volume":"89","author":"G Wollmann","year":"2015","journal-title":"J Virol"},{"issue":"3","key":"ppat.1010658.ref030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biologicals.2005.03.009","article-title":"Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.","volume":"33","author":"TP Monath","year":"2005","journal-title":"Biologicals."},{"issue":"10","key":"ppat.1010658.ref031","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.","volume":"183","author":"RB Tesh","year":"2001","journal-title":"J Infect Dis"},{"issue":"1","key":"ppat.1010658.ref032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2010.11.003","article-title":"The role of non-human primates in the neurological safety of live viral vaccines (review).","volume":"39","author":"I. Levenbook","year":"2011","journal-title":"Biologicals."},{"issue":"6","key":"ppat.1010658.ref033","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"THE effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus","volume":"65","author":"M Theiler","year":"1937","journal-title":"J Exp Med"},{"issue":"22","key":"ppat.1010658.ref034","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"J Arroyo","year":"2004","journal-title":"J Virol"},{"issue":"3","key":"ppat.1010658.ref035","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"CE Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ppat.1010658.ref036","unstructured":"World Health Organization Annex 5 Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines Replacement of Annex 2 of WHO Technical Report Series, No. 872 and of the Amendment to that annex in WHO Technical Report Series, No. 964, 2012 https:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_978_Annex_5.pdf?ua=1"},{"issue":"6","key":"ppat.1010658.ref037","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3201\/eid2506.181620","article-title":"Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease","volume":"25","author":"C. E. Mire","year":"2019","journal-title":"Emerging infectious diseases"},{"issue":"146","key":"ppat.1010658.ref038","doi-asserted-by":"crossref","first-page":"146ra107","DOI":"10.1126\/scitranslmed.3004241","article-title":"A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge","volume":"4","author":"KN Bossart","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"ppat.1010658.ref039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"JE Johnson","year":"2007","journal-title":"Virology"},{"issue":"17","key":"ppat.1010658.ref040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM200004273421701","article-title":"Clinical features of Nipah virus encephalitis among pig farmers in Malaysia","volume":"342","author":"KJ Goh","year":"2000","journal-title":"N Engl J Med"},{"key":"ppat.1010658.ref041","doi-asserted-by":"crossref","first-page":"634827","DOI":"10.3389\/fneur.2021.634827","article-title":"Neurologic Manifestations of the World Health Organization\u2019s List of Pandemic and Epidemic Diseases.","volume":"12","author":"CRS McEntire","year":"2021","journal-title":"Front Neurol."},{"issue":"3","key":"ppat.1010658.ref042","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/vaccines9030190","article-title":"Development of Pandemic Vaccines: ERVEBO Case Study.","volume":"9","author":"J Wolf","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"3","key":"ppat.1010658.ref043","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.coviro.2012.03.006","article-title":"Hendra and Nipah viruses: why are they so deadly?","volume":"2","author":"GA Marsh","year":"2012","journal-title":"Curr Opin Virol."},{"key":"ppat.1010658.ref044","first-page":"127","article-title":"Neurovirulence.","volume":"101","author":"D Wood","year":"1999","journal-title":"Dev Biol Stand"},{"issue":"4","key":"ppat.1010658.ref045","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1128\/JVI.76.4.1932-1943.2002","article-title":"Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines","volume":"76","author":"TP Monath","year":"2002","journal-title":"J Virol"},{"issue":"1","key":"ppat.1010658.ref046","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14760584.2018.1406800","article-title":"The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.","volume":"17","author":"CC Ferreira","year":"2018","journal-title":"Expert Rev Vaccines."},{"key":"ppat.1010658.ref047","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/oxfordjournals.aje.a118877","article-title":"Behavior of 17D yellow fever virus in rhesus monkeys: Relation to substrain, dose, and neural or extraneural inoculation","volume":"38","author":"J.P. Fox","year":"1943","journal-title":"Am. J. Epidemiol"},{"issue":"5","key":"ppat.1010658.ref048","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007-13.","volume":"23","author":"NP Lindsey","year":"2016","journal-title":"J Travel Med"},{"issue":"48","key":"ppat.1010658.ref049","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"NP Lindsey","year":"2008","journal-title":"Vaccine"},{"issue":"25","key":"ppat.1010658.ref050","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Yellow Fever Vaccine Safety Working Group","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"ppat.1010658.ref051","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0042-6822(03)00583-X","article-title":"Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys","volume":"316","author":"RS Marchevsky","year":"2003","journal-title":"Virology"},{"key":"ppat.1010658.ref052","author":"National Research Council","year":"2011","journal-title":"Guide for the Care and Use of Laboratory Animals: Eighth Edition"},{"issue":"10","key":"ppat.1010658.ref053","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"M Garbutt","year":"2004","journal-title":"J Virol"},{"key":"ppat.1010658.ref054","first-page":"493","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"LJ Reed","year":"1938","journal-title":"Amer. J. Hyg"},{"key":"ppat.1010658.ref055","unstructured":"European Pharmacopoeia 5.0, 01\/2005:2060, [12.6.18]. Tests for neurovirulence of live virus vaccines"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1010658","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T14:20:05Z","timestamp":1657290005000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010658"}},"subtitle":[],"editor":[{"given":"Amy L.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010658","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}